针对标准方案无应答的肝硬化患者采用三剂双倍剂量强化乙肝再接种方案:一项开放标签随机临床试验
本研究纳入120例对前三剂40 µg乙肝疫苗无应答的肝硬化患者(72.5%为失代偿期),按1:1随机分为经典组(第6个月单剂40 µg加强)与实验组(再接种三剂40 µg,每月一次)。实验组抗-HBs≥10 mIU/mL的应答率(意向性分析)为46.7%,高于经典组的25%(OR 2.63,p=0.013);在Child A、MELD<15和MELD-Na<15患者中实验组应答率也更高,但更晚期肝病患者未从强化方案中获益,两组安全性相似。
要点
- 对前三剂40 µg乙肝疫苗无应答的肝硬化患者,再接种三剂40 µg方案优于单剂40 µg加强。
- 实验组意向性分析应答率46.7%,经典组25%(OR 2.63,p=0.013)。
- Child A、MELD<15和MELD-Na<15患者从强化方案中获益,更晚期肝病患者未获益。
核心结论
- 对前三剂40 µg乙肝疫苗无应答的肝硬化患者,再接种三剂40 µg方案获得的应答率显著优于单剂40 µg加强。
研究设计与样本
- 开放标签随机临床试验,共纳入120例肝硬化患者(72.5%为失代偿期),按1:1随机分为经典组(第6个月单剂40 µg加强)与实验组(再接种三剂40 µg,每月一次)。
- 主要结局为接种后抗乙肝表面抗体水平≥10 mIU/mL的比率。
- 试验注册号NCT01884415。
主要发现
- 意向性分析应答率实验组为46.7%,经典组为25%(OR 2.63,p=0.013)。
- Child A患者中实验组应答率68% vs 经典组31%(OR 4.72,p=0.007)。
- MELD<15患者中实验组应答率50% vs 经典组24.4%(OR 3.09,p=0.012)。
- MELD-Na<15患者中实验组应答率53.8% vs 经典组24.4%(OR 3.62,p=0.007)。
- 更晚期肝病患者未从强化方案中获益;两种方案安全性相似。
关键数值与推荐
- 应答判定标准为接种后抗乙肝表面抗体水平≥10 mIU/mL。
- 经典组为第6个月单剂40 µg加强;实验组为再接种三剂40 µg,每月一次。
- 多因素分析显示,在三个校正肝硬化严重程度等效的logistic回归模型中,实验方案均与应答独立相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to compare the response rates between two different hepatitis B virus vaccination schedules for cirrhotic subjects who were non-responders to the first three 40 µg doses (month 0-1-2), and identify factors associated with the final response. DESIGN: A total of 120 cirrhotic patients (72.5% decompensated) were randomised at a 1:1 ratio to receive a single 40 µg booster vaccination at month 6 (classical arm) versus an additional round of three new 40 µg doses administered at monthly intervals (experimental arm). The main outcome was the rate of postvaccinal anti-hepatitis B surface antibodies levels ≥10 mIU/mL. RESULTS: Efficacy by ITT analysis was higher in the experimental arm (46.7%) than in the classical one (25%); OR 2.63, p=0.013. The experimental arm increased response rates compared with the classical one from 31% to 68% (OR 4.72; p=0.007), from 24.4% to 50% (OR 3.09; p=0.012) and from 24.4% to 53.8% (OR 3.62; p=0.007), in Child A, Model for End-Stage Liver Disease (MELD) <15 and MELD-Na<15 patients, respectively. Patients with more advanced liver disease did not benefit from the reinforced scheme. Both regimens showed similar safety profiles. Multivariable analysis showed that the experimental treatment was independently response associated when adjusted across three logistic regression models indicating equivalent cirrhosis severity. CONCLUSION: For cirrhotic patients, the revaccination of non-responders to the first three dose cycle, with three additional 40 µg doses, achieved significantly better response rates to those obtained with an isolated 40 µg booster dose. TRIAL REGISTRATION NUMBER: NCT01884415.
引用
- Giráldez-Gallego Á, Rodríguez-Seguel EDP, Valencia-Martín R, et al. Three double-dose reinforced hepatitis B revaccination scheme for patients with cirrhosis unresponsive to the standard regimen: an open-label randomised clinical trial. Gut. 2023. PMID: 36963815. doi:10.1136/gutjnl-2022-328222
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。